Pilar Biosciences seeks to make precision medicine a first-line therapy for cancer patients


Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.